Clinical Trials Logo

Filter by:
NCT ID: NCT02494986 Active, not recruiting - Clinical trials for Human Immunodeficiency Virus Type 1

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

Start date: July 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.

NCT ID: NCT02477826 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

CheckMate 227
Start date: August 5, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

NCT ID: NCT02445391 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Start date: October 20, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

NCT ID: NCT02441426 Active, not recruiting - Malnutrition Clinical Trials

Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development

MAL-ED
Start date: November 2008
Phase: N/A
Study type: Observational

Malnutrition is considered one of the most prevalent risk factors for morbidity and mortality in children under five. An estimated 20% of children in the developing world are malnourished [1] and poor nutrition is linked to more than half of all child deaths worldwide [2]. Malnutrition in early childhood may lead to cognitive and physical deficits and may cause similar deficits in future generations as malnourished mothers give birth to low birth weight children [3]. In addition, malnutrition increases susceptibility and incidence of infections and is associated with diminished response to vaccines. The MAL-ED Project is designed to determine the impact of enteric infections/diarrhea that alter gut function and impair children's nutrition, growth and development to help develop new intervention strategies that can break the vicious enteric infection-malnutrition cycle and reduce its global burden. The overall objective of the MAL-ED Project is to quantify the associations of specific enteric pathogens, measures of physical and mental development, micronutrient malnutrition, gut function biomarkers, the gut microbiome, and immune responses in very young children in resource-limited settings across eight sites that vary by culture, economics, geography, and climate. The central hypothesis of the MAL-ED Project is that infection (and co-infection) with specific enteropathogens leads to impaired growth and development and to diminished immune response to orally administered vaccines by causing intestinal inflammation and/or by altering intestinal barrier and absorptive function. Data analyses will test for associations between enteropathogen infections and growth/development to help illuminate: - which micro-organisms or mixed infections are most frequently associated with growth faltering and poor development; and - at what age specific infections cause the most disruption to growth and development and impair immune response.

NCT ID: NCT02440386 Active, not recruiting - HIV Clinical Trials

iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care

iLink
Start date: April 2015
Phase: N/A
Study type: Interventional

The iLink Study examines whether a Conditional Economic Incentive (CEI) may be an effective tool for improving linkage to HIV treatment and care following referral for antiretroviral therapy (ART) services from a mobile health clinic in Cape Town, South Africa. The study examines the feasibility and acceptability of using a R300 (approximately $25 as of April 2015) voucher - that is exchanged for cash upon initiation of ART within 3 months - to increase the uptake of ART among men and women living in low-income areas. This pilot study (n=64) includes a randomised control trial, follow-up telephone calls and medical record reviews, and in-depth interviews.

NCT ID: NCT02437201 Active, not recruiting - Clinical trials for Violence Against Women

Study of Liberty Program on Women's Health and Intimate Partner Violence

Start date: July 2015
Phase: N/A
Study type: Interventional

Previous studies indicated high frequency of abuse in families and its consequences. Considering the importance of interventions such as educational interventions, in order to increase women's abilities to prevent abusive behaviors, the current research aims to determine the impact of an Liberty program on prevention of violence against women and propose solutions for less damages and consequences.

NCT ID: NCT02404038 Active, not recruiting - HIV Clinical Trials

A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods

UChoose
Start date: July 2015
Phase: N/A
Study type: Interventional

This study will enrol sexually active, healthy girls aged 16-17 to assess and compare the acceptability and preference for a monthly vaginal ring, bi-monthly injectable contraception or daily dose oral contraception, as proxy for female-controlled ARV-based HIV prevention methods.

NCT ID: NCT02388906 Active, not recruiting - Melanoma Clinical Trials

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

CheckMate 238
Start date: March 19, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

NCT ID: NCT02367040 Active, not recruiting - Clinical trials for Lymphoma,Non-Hodgkin

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

CHRONOS-3
Start date: August 3, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.

NCT ID: NCT02362503 Active, not recruiting - HIV Infections Clinical Trials

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Start date: February 23, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.